Barinthus Biotherapeutics plc – NASDAQ:BRNS
Barinthus Biotherapeutics stock price today
Barinthus Biotherapeutics stock price monthly change
Barinthus Biotherapeutics stock price quarterly change
Barinthus Biotherapeutics stock price yearly change
Barinthus Biotherapeutics key metrics
Market Cap | 45.47M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.84 |
Revenue | N/A |
EBITDA | -69.22M |
Income | -70.79M |
Revenue Q/Q | -100% |
Revenue Y/Y | -81.08% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBarinthus Biotherapeutics stock price history
Barinthus Biotherapeutics stock forecast
Barinthus Biotherapeutics financial statements
| Jun 2023 | 334K | -23.80M | -7126.35% |
|---|---|---|---|
| Sep 2023 | 0 | -14.07M | |
| Dec 2023 | 5.36M | -17.44M | -324.88% |
| Mar 2024 | 0 | -15.48M |
| Sep 2025 | 0 | -28.18M | |
|---|---|---|---|
| Oct 2025 | 0 | -18.48M | |
| Dec 2025 | 0 | -27.74M | |
| Dec 2025 | 0 | -18.74M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 246128000 | 28.66M | 11.65% |
|---|---|---|---|
| Sep 2023 | 229970000 | 34.36M | 14.94% |
| Dec 2023 | 214506000 | 27.51M | 12.83% |
| Mar 2024 | 199482000 | 27.46M | 13.77% |
| Jun 2023 | -16.95M | -3.02M | 28K |
|---|---|---|---|
| Sep 2023 | -11.19M | -36K | 46K |
| Dec 2023 | -19.60M | 153K | 109K |
| Mar 2024 | -11.81M | -307.82K | 502.71K |
Barinthus Biotherapeutics alternative data
| Dec 2023 | 107 |
|---|---|
| Jan 2024 | 107 |
| Feb 2024 | 107 |
| Mar 2024 | 107 |
| Apr 2024 | 107 |
| May 2024 | 130 |
| Jun 2024 | 130 |
| Jul 2024 | 130 |
Barinthus Biotherapeutics other data
-
What's the price of Barinthus Biotherapeutics stock today?
One share of Barinthus Biotherapeutics stock can currently be purchased for approximately $1.06.
-
When is Barinthus Biotherapeutics's next earnings date?
Unfortunately, Barinthus Biotherapeutics's (BRNS) next earnings date is currently unknown.
-
Does Barinthus Biotherapeutics pay dividends?
No, Barinthus Biotherapeutics does not pay dividends.
-
How much money does Barinthus Biotherapeutics make?
Barinthus Biotherapeutics has a market capitalization of 45.47M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 98.21% to 802K US dollars.
-
What is Barinthus Biotherapeutics's stock symbol?
Barinthus Biotherapeutics plc is traded on the NASDAQ under the ticker symbol "BRNS".
-
What is Barinthus Biotherapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Barinthus Biotherapeutics?
Shares of Barinthus Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Barinthus Biotherapeutics have?
As Jul 2024, Barinthus Biotherapeutics employs 130 workers, which is 21% more then previous quarter.
-
When Barinthus Biotherapeutics went public?
Barinthus Biotherapeutics plc is publicly traded company for more then 4 years since IPO on 30 Apr 2021.
-
What is Barinthus Biotherapeutics's official website?
The official website for Barinthus Biotherapeutics is barinthusbio.com.
-
How can i contact Barinthus Biotherapeutics?
Barinthus Biotherapeutics can be reached via phone at +44 1865 818808.
Barinthus Biotherapeutics company profile:
Barinthus Biotherapeutics plc
barinthusbio.comNASDAQ
130
Biotechnology
Healthcare
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
Harwell, OX11 0DF
CIK: 0001828185
ISIN: US91864C1071
:
